DUBLIN, IRELAND--(Marketwire - April 02, 2008) - Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets and the market leader in adult haemoglobinopathy detection, is pleased to announce the introduction of its GeneSys™ platform for infant haemoglobinopathies. The GeneSys™ system will be the first on the market to offer a fully automated approach for newborn screening while providing positive identification for all major infant haemoglobin variants. The system also offers the unique time saving capability of allowing laboratories to run a confirmatory test on the same instrument for all positive results.
